What happened
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) closed an approximately $5.6 million PIPE and said existing significant shareholder John Paul DeJoria added $1.0 million. The closing occurred on October 5, 2026, when the company agreed to issue 4,843,300 shares of common stock at $1.16 each. That price was a 5% discount to the applicable 10-day VWAP, and the securities were only common stock.
Telomir said other existing shareholders and new investors also participated, and the gross proceeds are before fees and other offering expenses. The company said it plans to use the proceeds for Telomir-Zn clinical development, working capital and general corporate purposes. The company said the FDA cleared Telomir-Zn's IND for a first-in-human Phase 1/2 trial in advanced or metastatic triple-negative breast cancer. The Phase 1 portion is designed to assess safety, tolerability, dose selection, biomarkers and preliminary antitumor activity.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Gross proceeds | $5.6 million | SEC 8-K | |
| John Paul DeJoria investment | $1.0 million | SEC 8-K | |
| Shares issued | 4,843,300 shares | SEC 8-K | |
| Purchase price | $1.16 per share | SEC 8-K | |
| Placement-agent fee | $455,000 | SEC 8-K |
Why it matters
OptimistFi's case is that TELO needs credible clinical or regulatory progress before cash burn forces punitive financing. This financing funds the next development step, but it still shows reliance on equity. DeJoria's $1.0 million contribution equals about 17.9% of the gross proceeds, so the anchor check is material but not decisive.
Telomir also said the cash placement-agent fee payable to Alexander Capital was approximately $455,000, which adds another financing cost. The financing also came without investor warrants or convertible securities. The filing still shows only an approximately $5.6 million raise before expenses, so it does not remove financing risk.
Browse: stock research on every company OptimistFi covers
What's next
Telomir said it will file a registration statement with the SEC within 30 days of the October 5 closing to cover resale of the shares. Meeting that deadline would show the transaction is moving on the timetable the company disclosed, while a delay would weaken that execution signal. The clinical program remains the broader test, because the new money is earmarked for Telomir-Zn development and working capital.
More from OptimistFi
- TELO stock: the Telomir Pharmaceuticals thesis, its status and the next test to watch
- United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap
- Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
- Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 8-K — Current report filed October 6, 2026, reporting the private placement.
- Exhibit 99.1 press release — Press release dated October 6, 2026 announcing the financing.
Read the full OptimistFi thesis on Telomir Pharmaceuticals, Inc.: https://optimistfi.com/stocks/TELO
See what would break the Telomir Pharmaceuticals, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Telomir Pharmaceuticals, Inc. investment case, its status and the next test to watch live on the Telomir Pharmaceuticals, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
